Clomiphene citrate in infertile patients with polycystic ovary syndrome
DOI:
https://doi.org/10.47464/MetroCiencia/vol32/2/2024/38-44Keywords:
Clomiphene citrate, Polycystic ovary syndrome, Infertility, Ovulation, Ovulation induction, Pregnancy rateAbstract
Introduction: Polycystic ovary syndrome is an endocrine-metabolic pathological condition, of multifactorial etiology, characterized by hyperandrogenism, polycystic ovaries, and/or oligo-anovulation. In addition to diverse clinical manifestations including infertility, the main objective of this research is to describe clomiphene citrate in infertile patients with polycystic ovary syndrome, through a detailed systematic review, providing a comprehensive perspective on the efficacy, safety and clinical utility of this drug. Methodology: A non-experimental retrospective observational descriptive study that collected 178 articles under inclusion and exclusion criteria in the databases PubMed, Scielo, Science-Direct and EBSCO, using a search equation formulated by keywords and Boolean operators, after which they were screened using the PRISMA methodology. Results and Discussion: Clomiphene citrate is the main therapeutic measure to treat infertility in patients with polycystic ovary syndrome, because it induces ovulation and follicular maturation, and improves pregnancy and live birth rates. However, its use for more than 6 cycles is associated with an increased risk of drug resistance, along with other risk factors such as obesity or genetic predisposition. Conclusion: Clomiphene citrate remains the first-line drug for the treatment of infertility secondary to polycystic ovary syndrome because it significantly improves ovulation, pregnancy and live birth rates.
Downloads
References
Adashi EY, Cibula D, Peterson M, Azziz R. The polycystic ovary syndrome: the first 150 years of study. FS Rep. 2023;4(1):2-18. DOI: 10.1016/j.xfre.2022.12.002. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S2666334122001398
Suarez Coba BH, Borja Tapia PE, Vela Chasiluisa MA, Ontaneda Tenesaca CF. Diagnóstico y manejo del síndrome de ovario poliquístico. RECIMUNDO. 2019;3(3):970-1004. DOI: 10.26820/recimundo/3.(3).septiembre.2019.970-1004. Disponible: http://recimundo.com/index.php/es/article/view/557
Oliveira IEDG, De Lima JPMB, Pupe FM, Milhomem IDS, Coelho MEDH, Rabello JC, et al. O uso de Letrozol vs citrato de clomifeno para a indução ovulatória em mulheres com síndrome do ovário policístico: uma revisão de literatura. Braz J Dev. 2023;9(6):20495-509. DOI: 10.34117/bjdv9n6-115. Disponible en: https://ojs.brazilianjournals.com.br/ojs/index.php/BRJD/article/view/60886
Chang S, Dunaif A. Diagnosis of Polycystic Ovary Syndrome: Which Criteria to Use and When? Endocrinol Metab Clin North Am. 2021;50(1):11-23. DOI: 10.1016/j.ecl.2020.10.002. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0889852920300797?via%3Dihub
Castro Torres GR, Rojas Mendoza KJ, Min Kim H. Actualización sobre el síndrome de ovario poliquístico. Rev Medica Sinerg. 2023;8(2):e968. DOI: 10.31434/rms.v8i2.968. Disponible en: https://revistamedicasinergia.com/index.php/rms/article/view/968
Collée J, Mawet M, Tebache L, Nisolle M, Brichant G. Polycystic ovarian syndrome and infertility: overview and insights of the putative treatments. Gynecol Endocrinol. 2021;37(10):869-74. DOI: 10.1080/09513590.2021.1958310. Disponible en: https://www.tandfonline.com/doi/full/10.1080/09513590.2021.1958310
Alfaro Murillo G, Salas Ramírez B, Zúñiga Fallas A. Evaluación del síndrome de ovario poliquístico: herramientas diagnósticas y nuevas terapias. Rev Medica Sinerg. 2021;6(1):e635. DOI: 10.31434/rms.v6i1.635. Disponible en: https://revistamedicasinergia.com/index.php/rms/article/view/635
Ruiz Rodríguez R, Serrano Mera VK, Solis Guzmán PG, Montes Mendoza GA. Síntomas y tratamiento de pacientes diagnosticadas con síndrome de ovario poliquístico. RECIAMUC. 2020;4(4):125-33. DOI: 10.26820/reciamuc/4.(4).diciembre.2020.125-133. Disponible en: https://reciamuc.com/index.php/RECIAMUC/article/view/579
Teresa Sir P, Jessica Preisler R, Amiram Magendzo N. Síndrome de ovario poliquístico. diagnóstico y manejo. Rev Médica Clínica Las Condes. 2013;24(5):818-26. DOI: 10.1016/S0716-8640(13)70229-3. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0716864013702293
Vanhauwaert PS. Síndrome de ovario poliquístico e infertilidad. Rev Médica Clínica Las Condes. 2021;32(2):166-72. DOI: 10.1016/j.rmclc.2020.11.005. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0716864021000195
Organización Mundial de la Salud. [Internet]. La OMS alerta de que una de cada seis personas padece esterilidad [citado 13 de febrero de 2024]. Recuperado: https://www.who.int/es/news/item/04-04-2023-1-in-6-people-globally-affected-by-infertility. Disponible en: https://www.who.int/es/news/item/04-04-2023-1-in-6-people-globally-affected-by-infertility
El Telégrafo. El Telégrafo el Decano Digital [Internet]. 12 de diciembre de 2023. Infertilidad masculina en Ecuador, ¿qué alternativas existen para concebir? [citado 13 de febrero de 2024]. Recuperado: https://www.eltelegrafo.com.ec/noticias/actualidad/44/infertilidad-masculina-ecuador-alternativas-concebir. Disponible en: https://www.eltelegrafo.com.ec/noticias/actualidad/44/infertilidad-masculina-ecuador-alternativas-concebir
Aillón I, Recalde R. Actualización sobre el tratamiento de la infertilidad del síndrome de ovario poliquístico SOP. Cienc Ecuad Rev Científica. 2023;5(32):1-19. Disponible en: https://cienciaecuador.com.ec/index.php/ojs/article/view/145
Mejías Quintero ME. Síndrome de ovario poliquístico e infertilidad: Opciones de tratamiento. Rev Obstet Ginecol Venezuela. Sociedad de obstetricia y ginecología de Venezuela.; 2015;75(4):269-79. Disponible en: http://ve.scielo.org/scielo.php?script=sci_abstract&pid=S0048-77322015000400007&lng=es&nrm=iso&tlng=es
Bulsara J, Patel P, Soni A, Acharya S. A review: Brief insight into Polycystic Ovarian syndrome. Endocr Metab Sci. 2021;3:100085. DOI: 10.1016/j.endmts.2021.100085. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S266639612100008X
Gaba A, Hörath S, Hager M, Marculescu R, Ott J. Basal Anti Mullerian hormone levels and endometrial thickness at midcycle can predict the outcome after clomiphene citrate stimulation in anovulatory women with PCOS, a retrospective study. Arch Gynecol Obstet. 2019;300(6):1751-7. DOI: 10.1007/s00404-019-05359-7. Disponible en: http://link.springer.com/10.1007/s00404-019-05359-7
Sachdeva G, Gainder S, Suri V, Sachdeva N, Chopra S. Comparison of clinical, metabolic, hormonal, and ultrasound parameters among the clomiphene citrate-resistant and clomiphene citrate-sensitive polycystic ovary syndrome women. J Hum Reprod Sci. 2019;12(3):216. DOI: 10.4103/jhrs.JHRS_89_18. Disponible en: https://journals.lww.com/10.4103/jhrs.JHRS_89_18
Bordewijk EM, Weiss NS, Nahuis MJ, Kwee J, Lambeek AF, Van Unnik GA, et al. Gonadotrophins or clomiphene citrate in women with normogonadotropic anovulation and CC failure: does the endometrium matter? Hum Reprod. 2020;35(6):1319-24. DOI: 10.1093/humrep/deaa052. Disponible: https://academic.oup.com/humrep/article/35/6/1319/5849414
Tian Q-J. Consensus on Infertility Management and Fertility Preservation Related to Polycystic Ovary Syndrome. Reprod Dev Med. 2020;4(4):239-48. DOI: 10.4103/2096-2924.305930. Disponible en: https://journals.lww.com/10.4103/2096-2924.305930
Orias Vásquez M. Actualización del síndrome de ovario poliquístico. Rev Medica Sinerg. 2021;6(2):e648. DOI: 10.31434/rms.v6i2.648. Disponible en: https://revistamedicasinergia.com/index.php/rms/article/view/648
Li M, Ruan X, Mueck AO. Management strategy of infertility in polycystic ovary syndrome. Glob Health J. 2022;6(2):70-4. DOI: 10.1016/j.glohj.2022.03.002. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S2414644722000240
Yland JJ, Chiu Y-H, Rinaudo P, Hsu J, Hernán MA, Hernández-Díaz S. Emulating a target trial of the comparative effectiveness of clomiphene citrate and letrozole for ovulation induction. Hum Reprod. 2022;37(4):793-805. DOI: 10.1093/humrep/deac005. Disponible en: https://academic.oup.com/humrep/article/37/4/793/6511990
Rashid R, Mir SA, Kareem O, Ali T, Ara R, Malik A, et al. Polycystic ovarian syndrome-current pharmacotherapy and clinical implications. Taiwan J Obstet Gynecol. 2022;61(1):40-50. DOI: 10.1016/j.tjog.2021.11.009. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1028455921003132
Huyghe L, Robin C, Dumont A, Decanter C, Kyheng M, Dewailly D, et al. How to Choose the Optimal Starting Dose of Clomiphene Citrate (50 or 100 mg per Day) for a First Cycle of Ovulation Induction in Anovulatory PCOS Women? J Clin Med. 2023;12(15):4943. DOI: 10.3390/jcm12154943. Disponible en: https://www.mdpi.com/2077-0383/12/15/4943
Grädel F, Von Wolff M, Kohl Schwartz AS, Mitter VR. Low-dose clomiphene citrate does not reduce implantation and live birth rates in otherwise unstimulated modified natural cycle IVF—retrospective cohort study. Arch Gynecol Obstet. 2022;307(4):1073-81. DOI: 10.1007/s00404-022-06878-6. Disponible en: https://link.springer.com/10.1007/s00404-022-06878-6
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Diego Alexander González Ayala, Erika Jamilet Pereira Maldonado, Sixto Isaac Chiliquinga Villacis; Yazmin Lisseth Pinto Sánchez
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
